Internet Archive Scholar

Nationwide Seroprevalence of SARS-CoV-2 IgG Antibodies among Four Groups of Primary Health-Care Workers and Their Household Contacts 6 Months after the Initiation of the COVID-19 Vaccination Campaign in France: SeroPRIM Study Protocol

Marie Pouquet, Dorine Decarreaux, Pol Prévot-Monsacré, Corentin Hervé, Andréas Werner, Brigitte Grosgogeat, Hélène Blanché, Pascaline Rabiega, Julien Laupie, Fabienne Kochert, Nathalie Abraham, Jean-Marc Sebaoun (+12 others)
2021 Pathogens  

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (478.2 kB)
https://web.archive.org/web/20210722115611/https://res.mdpi.com/d_attachment/pathogens/pathogens-10-00911/article_deploy/pathogens-10-00911.pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL. The file type is application/pdf.

The protocol study will focus on the seroprevalence of IgG antibodies to SARS-CoV-2 achieved by vaccination and/or natural protection as well as the history, symptoms, and risk factors for SARS-CoV-2 in four primary health-care workers (PHCWs) and their household contacts in metropolitan France. Methods: Here, we propose a protocol for a nationwide survey to determine the seroprevalence of IgG antibodies to SARS-CoV-2 achieved by vaccination and/or natural protection in four PHCW populations
more » ... neral practitioners, pediatricians, pharmacists and assistants, and dentists and assistants) and their household contacts. Participants will be included from June to July 2021 (Phase 1) among PHCW populations located throughout metropolitan France. They will be asked to provide a range of demographic and behavioral information since the first SARS-CoV-2 wave and a self-sampled dried blood spot. Phase 1 will involve also a questionnaire and serological study of PHCWs' household contacts. Seroprevalence will be estimated using two ELISAs designed to detect specific IgG antibodies to SARS-CoV-2 in humoral fluid, and these results will be confirmed using a virus neutralization test. This study will be repeated from November to December 2021 (Phase 2) to evaluate the evolution of immune status achieved by vaccination and/or natural protection of PHCWs and to describe the history of exposure to SARS-CoV-2.
doi:10.3390/pathogens10070911 fatcat:6sd64wp4azhy7ol5tcwekk56fm
DOAJ
Citation

Marie Pouquet, Dorine Decarreaux, Pol Prévot-Monsacré, Corentin Hervé, Andréas Werner, Brigitte Grosgogeat, Hélène Blanché, Pascaline Rabiega, Julien Laupie, Fabienne Kochert, Nathalie Abraham, Jean-Marc Sebaoun, Xavier de Lamballerie, Remi Charrel, Cecile Souty, Ibrahima Camara, Jeanne Pergeline, Harold Noël, Caroline Guerrisi, Sylvie van der Werf, Fabrice Carrat, Thomas Hanslik, Thierry Blanchon, Alessandra Falchi. "Nationwide Seroprevalence of SARS-CoV-2 IgG Antibodies among Four Groups of Primary Health-Care Workers and Their Household Contacts 6 Months after the Initiation of the COVID-19 Vaccination Campaign in France: SeroPRIM Study Protocol." Pathogens 10.7 (2021) 911